Print this page
-
A Prospective Trial of Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for the Treatment of Metastatic Lung Cancer: SBRT Sensitization of the Programmed Death-1 (PD-1) Effect
Protocol: 031907Principal Investigator:
- David D'Ambrosio (Community Medical Center)
Applicable Disease Sites: Lung -
E4412: A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
Protocol: 011505Principal Investigator:
- Kevin David M.D (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Hodgkin's Lymphoma -
NCI/CTEP #9681: A Phase I Study of Cabozantinib plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary Tumors
Protocol: 051512Principal Investigator:
- Biren Saraiya M.D (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Kidney
Prostate
Urinary Bladder
Other Urinary -
A Basket Trial of Pembrolizumab in Patients with Advanced Solid Tumors and Genomic Instability (multi-center)
Protocol: 051709Principal Investigator:
- Janice Mehnert M.D (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Any Site -
BTCRC-LUN15-017: A Phase Ib/II Study of Anti-PD-1 Antibody Pembrolizumab and Imprime PGG for Patients with Metastatic Non-Small Cell Lung Cancer After Progression on First-Line Chemotherapy: Big Ten Cancer Research Consortium.
Protocol: 031703Principal Investigator:
- Jyoti Malhotra MD, MPH (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Lung -
BTCRC-LUN16-081: Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC).
Protocol: 031706Principal Investigator:
- Salma Jabbour M.D. (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Lung
